OBJECTIVES: Asenapine, an oral atypical antipsychotic (AA), was initially used for more severe bipolar I mixed disorder. Different propensity score (PS) methods were investigated to achieve balanced baseline characteristics between asenapine and four oral AA cohorts for eventual outcomes analyses.
IPTW-and SMR-Weighted Baseline Characteristics
• Using the IPTW method, many bipolar I mixed asenapine patients have weights (1/PS) >1.0, whereas the weights of the nonasenapine patients are <1.0 (1/[1-PS]). This resulted in weighted sample sizes of 1,457 for asenapine patients (rather than the 230 identified patients), 623 for olanzapine (rather than the 984 identified patients), and 1,700 for quetiapine (rather than the 3,056 identified patients). (Table 2 and Table 3 ) -Demographic imbalance remained between asenapine and each AA cohort. (Figure 2 and Figure 3 ) ( Table 2 and  Table 3 ) -Some clinical characteristics previously balanced in the un-weighted analyses were now unbalanced.
-IPTW improved baseline characteristics' balance with asenapine vs olanzapine and risperidone, but only slightly improved balance vs aripiprazole and quetiapine.
• With SMR weighting, asenapine patients are assigned a weight = 1.0 and the non-asenapine patients are assigned weights much less than 1.0 (PS/1-PS). This resulted in weighted sample sizes of 230 for asenapine (sample size unchanged), 232 for olanzapine (rather than the 984 identified patients), and 230 for quetiapine (rather than the 3,056 identified patients). (Table  2 and Table 3 ) -All baseline demographic and clinical characteristics were balanced post-SMR weighting. (Figure 2 and Figure 4) ( Table  2 and Table 3 )
Introduction
In a recent historical cohort study, asenapine, an oral AA, was found to be used among patients with more severe bipolar I mixed disorder when compared to aripiprazole, olanzapine, quetiapine, and risperidone users.
In order to achieve balance in the baseline characteristics between asenapine and each AA cohort, different PS methods (IPTW and SMR), were evaluated before the comparison of outcomes.
Objectives
• • Target Population: Adults (≥18 years old) with ≥1 prescription fill for any of the 5 aforementioned AAs of interest during the enrollment window (August 1, 2009 to December 31, 2010 . The first chronologically occurring AA was deemed the index AA if no claims for that AA were identified in the 6-month pre-index period. The first prescription fill for the index AA was the index date. Patients then had to be continuously enrolled from 6 months pre-index through 12 months post-index in medical and pharmacy benefits, have ≥1 medical claim with a diagnosis of bipolar I disorder mixed (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] 296.6x, in any position), no prescription for a depot antipsychotic ±2 months of the index date, and no concomitant schizophrenia.
• Time frame: The 6-month pre-index period was used to measure and evaluate the balance of baseline demographic and clinical characteristics among the cohorts.
Statistical Analysis
• Student's t-test was used to compare continuous measures and chi-squares for categorical measures between the asenapine and other AA cohorts. Based on the distributional properties of each measure under study, non-parametric tests were also utilized when appropriate.
• PS were derived using logistic regression models for asenapine and each AA cohort with baseline demographic and clinical characteristics as covariates. The following variables were used to compute PS: -Age, gender, plan type, prescribing physician specialty*, cardiovascular and metabolic conditions, prior bipolar I and II episodes, and prescriptions for specific somatic and psychotropic medications.
• IPTW and SMR weighting were assessed to achieve balance among the treatment cohorts.
1,2,3 -IPTW: 1/PS for the asenapine cohort and 1/(1-PS) for the comparator AA cohort.
-SMR: 1 (or PS/PS) for asenapine cohort and PS/(1-PS) for the comparator cohort.
• Un-weighted, and IPTW-and SMR-weighted baseline characteristics were compared using standardized differences, chisquares, and t-tests.
• Tables and figures are presented for asenapine compared to olanzapine and quetiapine. Data for all other comparators have not been provided due to space constraints.
*Prescribing physician specialty was assigned by proxy using the specialty of the provider noted on the medical claim associated with the index diagnosis. Key: AA -atypical antipsychotic; CCI -Charlson comorbidity index; CDHP -consumerdriven health plan; FFS -fee-for-service; HDHP -high-deductible health plan; HMO -health maintenance organization; PDGs -psychiatric diagnostic groups; POS -point of service; PPO -preferred provider organization; SD -standard deviation. † Percent may not add up to 100% as some patients have missing information. *Number of therapeutic classes for which prescriptions were filled in the 6-month pre-index period as classified by REDBOOK™. P-values in bold red <0.05.
Methods

Results
Characteristic
Table 1. Baseline Demographic and Clinical Characteristics PS Distribution
• PS distributions for asenapine-olanzapine overlapped to some degree, while PS of asenapine and the other comparators overlapped little to not at all. (Figures 1a and Figure 1b) • PS matching was ruled out as an option for removing bias, since a large number of asenapine patients would not have had a matching comparator patient, therefore excluding them from the analysis. As the asenapine population was small, retaining the maximum sample size was important. Key: AA -atypical antipsychotic; CCI -Charlson comorbidity index; CDHP -consumerdriven health plan; FFS -fee-for-service; HDHP -high-deductible health plan; HMO -health maintenance organization; IPTW -inverse probability treatment weights; PDGs -psychiatric diagnostic groups; POS -point of service; PPO -preferred provider organization; PSpropensity score; SD -standard deviation; SMR -standardized mortality ratio. † P value could not be obtained due to low numbers. *Number of therapeutic classes for which prescriptions were filled in the 6-month pre-index period as classified by REDBOOK™. **Normalized weights were used. P values in bold red <0.05. Key: AA -atypical antipsychotic; CCI -Charlson comorbidity index; CDHP -consumerdriven health plan; FFS -fee-for-service; HDHP -high-deductible health plan; HMO -health maintenance organization; IPTW -inverse probability treatment weights; PDGs -psychiatric diagnostic groups; POS -point of service; PPO -preferred provider organization; PSpropensity score; SD -standard deviation; SMR -standardized mortality ratio. † Percent may not add up to 100% as some patients have missing information. ‡ P value could not be obtained due to low numbers. *Number of therapeutic classes for which prescriptions were filled in the 6-month pre-index period as classified by REDBOOK™. **Normalized weights were used. P values in bold red <0.05.
Table 3. IPTW-and SMR-Weighted Baseline Characteristics: Asenapine vs Quetiapine
• The study findings are dependent on the accuracy of ICD-9-CM coding in claims files.
• Prescribing physician was implied from the physician specialty on the medical claim for bipolar I mixed disorder closest to the index prescription.
Limitations
• The IPTW method simulates a population whose distribution of risk factors equals the distribution of risk factors of the entire sample (ie, the average patient) and provides a measure of the average treatment effect. By comparison, the SMR method simulates a population whose distribution of risk factors equals the distribution of risk factors among the "treated population" (ie, asenapine) and provides a measure of the average treatment effect on the treated patient.
• As the goal of the larger study was to compare treatment patterns and outcomes of bipolar I mixed patients prescribed asenapine with patients prescribed each of the other AAs, SMR weighting was preferred to meet the overall study objectives.
• SMR, a less common PS method, resulted in balanced baseline characteristics for the asenapine cohort with each of the other AA cohorts. SMR should be considered when IPTW leaves an imbalance and the cohort of primary interest differs significantly from the broader underlying population to which it's being compared. 
Conclusions and Discussion
References
